|Bid||1.99 x 600|
|Ask||2.49 x 5000|
|Day's range||2.00 - 2.09|
|52-week range||1.28 - 2.45|
|PE ratio (TTM)||0.84|
|Earnings date||27 Mar 2017 - 31 Mar 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||15.55|
ProPhase Labs, Inc. today reported that that on June 12, 2017 it entered into a Stock Purchase Agreement with each of Mark S. Leventhal, a former director of the Company, and certain other persons and ...
Categories: Yahoo FinanceGet free summary analysis ProPhase Labs, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of ProPhase Labs, Inc. – Mannatech, Incorporated, Reliv’ International, Inc., USANA Health Sciences, Inc., Nutraceutical International Corporation, Nature’s Sunshine Products, Inc., XOMA Corporation and Emisphere Technologies, Inc. (MTEX-US, RELV-US, ... Read more (Read more...)
ProPhase Labs, Inc. today reported its financial results for the three months ended March 31, 2017. As previously announced, effective March 29, 2017 and with the approval of the Company's stockholders, ...